Tubulin-IN-62 is a potent tubulin inhibitor targeting the colchicine binding site. It has an IC50 of 17.2 nM in SKOV3 cells and 19.3 nM in HCC827 cells. Tubulin-IN-62 inhibits microtubule polymerization, arrests the cell cycle at the G2/M phase, and induces apoptosis. In xenograft tumor models, it demonstrates significant antitumor efficacy with good tolerability. Tubulin-IN-62 is applicable for research on ovarian cancer and non-small cell lung cancer.

Tubulin-IN-62 (compound (S)-Q31) significantly inhibits the colony formation ability of SKOV3 and HCC827 cells at concentrations of 10-80 nM over 10 days. It also impedes the migration capacity of these cells when applied at the same concentration range for 24 hours. The compound demonstrates antiproliferative effects and induces apoptosis in SKOV3 and HCC827 cells at concentrations of 10-80 nM over 48 hours, and apoptosis is further induced at lower concentrations (5-40 nM) within the same timeframe. Additionally, Tubulin-IN-62 causes cell cycle arrest at the G2/M phase in these cells when treated with concentrations of 10-80 nM for 24 hours. This G2/M phase arrest is linked with the downregulation of Cdc-25c, cyclin B1, and Cdc-2 expression within 48 hours. Tubulin-IN-62 also exhibits microtubule polymerization inhibition activity at 2.5-20 μM after 80 minutes and at 40 nM after 24 hours, disrupting the microtubule network in SKOV3 and HCC827 cells.

Tubulin-IN-62 (compound (S)-Q31), administered intravenously at 2 or 4 mg/kg every other day for a total of 12 doses, demonstrated antitumor efficacy in a female Balb/c mouse xenograft model with SKOV3 cells. The compound effectively inhibited cell proliferation and induced apoptosis, with no significant pathological changes observed in major organs, indicating favorable safety.